 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...124125126127128129130131132133134...143144» |
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT (clinicaltrials.gov) - Mar 3, 2015
P3, N=40, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center.
Trial primary completion date: Aug 2015 --> Aug 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Perjeta (pertuzumab) / Roche
Enrollment change, Trial termination, Combination therapy, Metastases: Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 23, 2015
P1/2, N=17, Terminated, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Aug 2015 --> Aug 2016 N=50 --> 17 | Active, not recruiting --> Terminated
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Trial primary completion date: S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride (clinicaltrials.gov) - Feb 19, 2015
P=N/A, N=140, Recruiting, Sponsor: Southwest Oncology Group
N=50 --> 17 | Active, not recruiting --> Terminated Trial primary completion date: Jul 2015 --> Nov 2015
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver (clinicaltrials.gov) - Feb 19, 2015
P1, N=140, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jul 2015 --> Nov 2015 Trial primary completion date: Sep 2015 --> Sep 2016
- duligotuzumab (MEHD7945A) / Roche
Trial completion, Trial primary completion date, Metastases: Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Feb 19, 2015
P2, N=135, Completed, Sponsor: Genentech, Inc.
Trial primary completion date: Sep 2015 --> Sep 2016 Recruiting --> Completed | Trial primary completion date: Jun 2015 --> Nov 2014
- |||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - Feb 19, 2015
P2, N=80, Completed, Sponsor: University of Pittsburgh
Recruiting --> Completed | Trial primary completion date: Jun 2015 --> Nov 2014 Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Combination therapy: Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0 (clinicaltrials.gov) - Feb 12, 2015
P1, N=21, Active, not recruiting, Sponsor: Lund University Hospital
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date, Trial primary completion date, Metastases: Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) (clinicaltrials.gov) - Feb 11, 2015
P2, N=42, Not yet recruiting, Sponsor: Centre Leon Berard
Recruiting --> Active, not recruiting Initiation date: Jan 2014 --> Jun 2015 | Trial primary completion date: Apr 2016 --> Sep 2017
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: COMMENCE: A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck (clinicaltrials.gov) - Feb 10, 2015
P1/2, N=120, Recruiting, Sponsor: Radboud University
Initiation date: Jan 2014 --> Jun 2015 | Trial primary completion date: Apr 2016 --> Sep 2017 Trial primary completion date: Aug 2016 --> Aug 2017
- ||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Surgery: NCCTG N0147: Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer (clinicaltrials.gov) - Feb 9, 2015
P3, N=3397, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Aug 2016 --> Aug 2017 Active, not recruiting --> Completed
- gedatolisib (PF-05212384) / Celcuity
Enrollment change, Metastases: A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 6, 2015
P2, N=150, Terminated, Sponsor: Pfizer
Active, not recruiting --> Completed N=15 --> 150
- ||| Ojemda (tovorafenib) / Day One Biopharma, alisertib (MLN8237) / Puma
Enrollment open, Combination therapy, Metastases: A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies (clinicaltrials.gov) - Feb 6, 2015
P1b, N=103, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
N=15 --> 150 Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Feb 5, 2015
P1, N=30, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2014 --> Aug 2015
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open: Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Feb 5, 2015
P2, N=70, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Aug 2014 --> Aug 2015 Not yet recruiting --> Recruiting
- | patritumab (U3-1287) / Amgen, Daiichi Sankyo
New P1 trial, Combination therapy, Metastases: Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer (clinicaltrials.gov) - Jan 30, 2015
P1b, N=18, Recruiting, Sponsor: Daiichi Sankyo Inc.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors (clinicaltrials.gov) - Jan 28, 2015
P1, N=22, Recruiting, Sponsor: Georgetown University
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2014 --> Dec 2015
- || lumretuzumab (RG7116) / Roche
Trial primary completion date, Combination therapy, Metastases: A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin (clinicaltrials.gov) - Jan 28, 2015
P1, N=182, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Aug 2015 --> Nov 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial termination, Metastases: Colorectal Cancer (CRC) Cetuximab Elderly Frail (clinicaltrials.gov) - Jan 28, 2015
P2, N=5, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Trial primary completion date: Aug 2015 --> Nov 2015 N=150 --> 5 | Recruiting --> Terminated; poor accrual
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: H&N07: Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jan 26, 2015
P3, N=320, Completed, Sponsor: Associazione Volontari Pazienti Oncologici
N=150 --> 5 | Recruiting --> Terminated; poor accrual Recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial primary completion date: Investigation of the Effect of Vitamin K3-lotion for the Treatment of Cetuximab Induced Folliculitis (clinicaltrials.gov) - Jan 22, 2015
P2, N=30, Completed, Sponsor: Per Pfeiffer
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jan 2012 --> Dec 2013
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Nordic 8 - A Phase II Trial (clinicaltrials.gov) - Jan 22, 2015
P2, N=180, Recruiting, Sponsor: Per Pfeiffer
Recruiting --> Completed | Trial primary completion date: Jan 2012 --> Dec 2013 Trial primary completion date: Sep 2014 --> Dec 2016
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Combination therapy: CECAVI: Cetuximab in Combination With Chemotherapy for Patients With Head and Neck Cancer (clinicaltrials.gov) - Jan 22, 2015
P2, N=55, Recruiting, Sponsor: Per Pfeiffer
Trial primary completion date: Sep 2014 --> Dec 2016 Trial primary completion date: May 2012 --> Sep 2012
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial primary completion date, Monotherapy, Metastases: SAKK 41/10: Cetuximab for Elderly Patients With mCRC (clinicaltrials.gov) - Jan 22, 2015
P2, N=78, Active, not recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Trial primary completion date: May 2012 --> Sep 2012 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Dec 2015
- pegvorhyaluronidase alfa (PEGPH20) / Halozyme, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection (clinicaltrials.gov) - Jan 20, 2015
P=N/A, N=10, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Sep 2015 --> Sep 2016
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date, Trial primary completion date, Metastases: Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma (clinicaltrials.gov) - Jan 15, 2015
P2, N=37, Recruiting, Sponsor: University of Pittsburgh
Trial primary completion date: Sep 2015 --> Sep 2016 Initiation date: Oct 2011 --> Oct 2013 | Trial primary completion date: Oct 2013 --> Oct 2016
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Combination therapy, Metastases: REGAIN: Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study (clinicaltrials.gov) - Jan 14, 2015
P2, N=60, Recruiting, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Initiation date: Oct 2011 --> Oct 2013 | Trial primary completion date: Oct 2013 --> Oct 2016 Not yet recruiting --> Recruiting
- ||| Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment change, Trial primary completion date, Metastases: Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 13, 2015
P1/2, N=150, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting N=124 --> 150 | Trial primary completion date: Mar 2017 --> Aug 2016
- luminespib (AUY922) / Ligand, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 8, 2015
P1, N=18, Active, not recruiting, Sponsor: Swedish Medical Center
N=124 --> 150 | Trial primary completion date: Mar 2017 --> Aug 2016 Recruiting --> Active, not recruiting
- | dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
Trial completion, Enrollment change, Combination therapy, Metastases: A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025) (clinicaltrials.gov) - Jan 7, 2015
P2a, N=11, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=70 --> 11
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 6, 2015
P1, N=83, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | N=70 --> 11 Trial primary completion date: Apr 2015 --> Apr 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer (clinicaltrials.gov) - Jan 2, 2015
P1, N=64, Completed, Sponsor: Gynecologic Oncology Group
Trial primary completion date: Apr 2015 --> Apr 2016 N=100 --> 64
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Trial primary completion date, Metastases: PACER: A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 30, 2014
P2, N=41, Recruiting, Sponsor: National Cancer Institute, Naples
N=100 --> 64 Trial primary completion date: Jul 2014 --> Jul 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer (clinicaltrials.gov) - Dec 30, 2014
P2, N=108, Active, not recruiting, Sponsor: National Cancer Institute, Naples
Trial primary completion date: Jul 2014 --> Jul 2015 Trial primary completion date: Feb 2014 --> Mar 2015
- ||| Ojemda (tovorafenib) / Day One Biopharma, alisertib (MLN8237) / Puma
New P1 trial, Combination therapy, Metastases: A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies (clinicaltrials.gov) - Dec 30, 2014
P1b, N=103, Not yet recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
- ||| Biomarker, Enrollment change, MSi-H Biomarker, PD(L)-1 Biomarker, Metastases: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Dec 24, 2014
P2, N=610, Not yet recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Feb 2014 --> Mar 2015 N=1680 --> 610
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Surgery, Metastases: Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer (clinicaltrials.gov) - Dec 24, 2014
P=N/A, N=20, Not yet recruiting, Sponsor: Rutgers, The State University of New Jersey
- | Keytruda (pembrolizumab) / Merck (MSD)
New P1/2 trial, Metastases: Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer (clinicaltrials.gov) - Dec 19, 2014
P1/2, N=90, Recruiting, Sponsor: Western Regional Medical Center
- gedatolisib (PF-05212384) / Celcuity
Enrollment change, Trial termination, Metastases: A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 17, 2014
P2, N=15, Terminated, Sponsor: Pfizer
N=150 --> 15 | Recruiting --> Terminated; Enrollment to the study was terminated on 11Nvo2014 due to slow recruitment. There were no safety or efficacy issues that contributed to this decision.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Combination therapy, Metastases: REGAIN: Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study (clinicaltrials.gov) - Dec 16, 2014
P2, N=60, Not yet recruiting, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Surgery, Metastases: COMBATAC: Combined Anticancer Treatment of Advanced Colon Cancer (clinicaltrials.gov) - Dec 12, 2014
P2, N=60, Active, not recruiting, Sponsor: University of Regensburg
There were no safety or efficacy issues that contributed to this decision. Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Cetuximab Rechallenge Study (clinicaltrials.gov) - Dec 12, 2014
P2, N=35, Recruiting, Sponsor: Chinese University of Hong Kong
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2015 --> Apr 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Trial primary completion date, Metastases: MAESTRO HN: Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy (clinicaltrials.gov) - Dec 12, 2014
P2, N=80, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Apr 2015 --> Apr 2016 Trial primary completion date: Jan 2015 --> Jan 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial primary completion date, Metastases: CEBIFOX: Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 12, 2014
P2, N=59, Active, not recruiting, Sponsor: Martin Schuler, Prof. Dr. med.
Trial primary completion date: Jan 2015 --> Jan 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2011 --> Mar 2015
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab (clinicaltrials.gov) - Dec 10, 2014
P2, N=60, Recruiting, Sponsor: University of Zurich
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2011 --> Mar 2015 Trial primary completion date: Nov 2015 --> Dec 2017
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma. (clinicaltrials.gov) - Dec 7, 2014
P2, N=18, Recruiting, Sponsor: University Hospital, Ghent
Trial primary completion date: Nov 2015 --> Dec 2017 Trial primary completion date: Sep 2013 --> Sep 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Trial primary completion date, Circulating tumor cells, Tumor cell, Metastases: CIRCUTEC: Circulating Tumor Cells as an Early Predictive head-and -Neck Squamous-cell Carcinoma (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=115, Recruiting, Sponsor: University Hospital, Montpellier
Trial primary completion date: Sep 2013 --> Sep 2015 Trial primary completion date: Apr 2014 --> Oct 2017
- || napabucasin (BBI608) / Sumitomo Pharma
Trial primary completion date, Metastases: A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Dec 6, 2014
P2, N=66, Recruiting, Sponsor: Boston Biomedical, Inc
Trial primary completion date: Apr 2014 --> Oct 2017 Trial primary completion date: Dec 2014 --> Dec 2015
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Everest 2: Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer (clinicaltrials.gov) - Dec 6, 2014
P2, N=375, Active, not recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
Trial primary completion date: Dec 2014 --> Dec 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2014 --> Mar 2015
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: COMETS: Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients (clinicaltrials.gov) - Dec 5, 2014
P3, N=350, Recruiting, Sponsor: Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2014 --> Mar 2015 Trial primary completion date: Dec 2013 --> Nov 2014
- Enrollment change, Trial withdrawal, Trial primary completion date, Combination therapy, Metastases: Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=0, Withdrawn, Sponsor: Universitaire Ziekenhuizen Leuven
Trial primary completion date: Dec 2013 --> Nov 2014 N=20 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2013 --> Dec 2014